Immune & Longevity Peptides: Thymosin Alpha-1, LL-37, Humanin, and MOTS-c

Overview

Immune and longevity peptides represent a diverse group of compounds that modulate immune function, cellular stress responses, and metabolic pathways associated with aging. This page examines four peptides at different stages of clinical development: Thymosin Alpha-1 (the most clinically established, approved in over 35 countries), LL-37 (a human antimicrobial peptide under investigation), Humanin (a mitochondrial-derived peptide with cytoprotective properties), and MOTS-c (a mitochondrial-derived peptide with metabolic effects).

These peptides operate through distinct biological systems. Thymosin Alpha-1 modulates adaptive immunity through T-cell maturation and dendritic cell activation (Dominari et al., 2016). LL-37 is part of the innate immune system's first line of defense against pathogens (Vandamme et al., 2012). Humanin and MOTS-c are mitochondrial-derived peptides (MDPs) — small peptides encoded within the mitochondrial genome that function as retrograde signaling molecules, communicating mitochondrial status to the cell and systemically (Hazafa et al., 2021; Kumagai et al., 2022).

At a Glance

A quick-reference overview of peptides in this category — key facts, evidence level, and estimated cost.

Head-to-Head Comparison

Thymosin Alpha-1 (Zadaxin)

What It Is

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland. It was first isolated by Dr. Allan Goldstein at the George Washington University in the 1970s from thymosin fraction 5, a partially purified preparation of bovine thymus. The synthetic version was developed by SciClone Pharmaceuticals and marketed as Zadaxin (Goldstein, 2001).

Mechanism of Action

• T-cell maturation: Promotes differentiation of immature T-cell precursors into mature, functional CD4+ and CD8+ T-cells
• Dendritic cell activation: Enhances antigen presentation by dendritic cells through Toll-like receptor (TLR) signaling, particularly TLR2 and TLR9
• NK cell activation: Increases natural killer cell cytotoxicity
• Cytokine modulation: Promotes Th1 immune responses (interferon-gamma, IL-2) while modulating inflammatory cytokines
• Immune reconstitution: Particularly effective in immunocompromised states where T-cell function is depressed

Source: Dominari et al., 2016; Goldstein, 2001.

Clinical Evidence

• Hepatitis B: Multiple randomized controlled trials demonstrate improved viral clearance and seroconversion rates when Tα1 is used alone or in combination with interferon-alpha. This is the primary approved indication in most countries (Goldstein, 2001)
• Hepatitis C: Studies show improved sustained virological response rates when combined with interferon-based regimens
• Cancer (adjuvant): Clinical trials in hepatocellular carcinoma, melanoma, and non-small cell lung cancer report improved immune parameters and some survival benefit when used as an adjunct to chemotherapy or immunotherapy (Dominari et al., 2016)
• Sepsis: Studies report reduced mortality in severe sepsis patients, attributed to immune reconstitution in the immunosuppressive phase of sepsis
• COVID-19: Several studies during the pandemic evaluated Tα1 for severe COVID-19, with some reporting improved lymphocyte counts and clinical outcomes, though results were mixed (2025)
• HIV: Studied as an adjunct to antiretroviral therapy for CD4+ T-cell recovery
• Vaccine adjuvant: Research demonstrates enhanced immune responses to influenza and hepatitis B vaccines in elderly and immunocompromised populations

Why not FDA-approved: Despite extensive international use, SciClone Pharmaceuticals did not pursue FDA approval in the US due to commercial and regulatory strategy considerations. The clinical evidence base, while substantial, consists largely of trials conducted outside the US that may not meet all FDA requirements for approval.

Dosing Context

Thymosin Alpha-1 is administered by subcutaneous injection. Dosing should be determined by a qualified healthcare provider based on the clinical indication and individual patient assessment. The Zadaxin prescribing information (in countries where it is approved) provides indication-specific dosing guidance.

Side Effects

• Reported as well-tolerated in published clinical trials
• Injection site reactions: Mild pain, redness, or swelling at injection site
• Flu-like symptoms: Occasional mild fever, fatigue, or myalgia
• Serious adverse events are rare in published literature
• Long-term safety data available from international post-marketing surveillance

Legal Status

• Approved in 35+ countries: Including China, Italy, India, Philippines, Mexico, Peru, and numerous others, primarily for hepatitis B/C and as an immune adjuvant
• United States: Not FDA-approved. Designated as an orphan drug by the FDA for hepatitis B and certain cancers. Available through compounding pharmacies and peptide suppliers.
• EU: Not centrally approved by EMA, though approved in some individual EU member states (Italy).

Cost

• Zadaxin (brand): Variable by country; generally $50–$100 per injection in countries where it is marketed
• Compounded (US): $200–$500 per month through peptide clinics and compounding pharmacies
• Research-grade: $50–$150 per vial from peptide suppliers

LL-37

What It Is

LL-37 is a 37-amino acid peptide that represents the active, mature form of human cathelicidin antimicrobial peptide (hCAP18/LL-37). It is the only cathelicidin identified in humans. LL-37 is produced by neutrophils, macrophages, epithelial cells, and other immune cells, and is found in body fluids including sweat, saliva, breast milk, and wound fluid. Its expression is regulated by vitamin D, linking vitamin D status to innate immune defense (Vandamme et al., 2012).

Mechanism of Action

• Direct antimicrobial: Disrupts microbial membranes through electrostatic interaction with negatively charged bacterial surfaces, forming pores that kill bacteria, fungi, and enveloped viruses
• Immune modulation: Recruits immune cells to sites of infection; modulates cytokine production; promotes dendritic cell maturation
• Wound healing: Stimulates keratinocyte migration, angiogenesis, and re-epithelialization
• Anti-biofilm: Disrupts and prevents bacterial biofilm formation
• LPS neutralization: Binds and neutralizes lipopolysaccharide (endotoxin), potentially reducing sepsis-related inflammation

Source: Vandamme et al., 2012; Mookherjee et al., 2020.

Clinical Evidence

• Wound healing: Preclinical studies demonstrate accelerated wound closure and reduced infection rates. Clinical development for chronic wounds is underway (Mookherjee et al., 2020)
• Infections: In vitro and animal studies show broad-spectrum antimicrobial activity against antibiotic-resistant organisms including MRSA and multidrug-resistant gram-negative bacteria (2025)
• Cystic fibrosis: Inhaled formulations studied for airway infections in CF patients
• Inflammatory skin conditions: LL-37 is paradoxically implicated in both defense and pathology — elevated LL-37 levels are found in rosacea and psoriasis lesions, where it may drive inflammation
• Cancer: Mixed data — some studies show anti-tumor effects while others suggest LL-37 may promote tumor growth in certain contexts

Limitations: LL-37 is expensive to synthesize at scale, susceptible to proteolytic degradation, and can be cytotoxic to host cells at high concentrations. Much of the clinical development focuses on modified analogs that address these limitations (Mookherjee et al., 2020).

Dosing Context

LL-37 is not approved for clinical use. Dosing should be determined by a qualified healthcare provider. The peptide is being studied in various formulations (topical, injectable, inhaled) at different dose ranges depending on the indication.

Side Effects

• Cytotoxicity: At high concentrations, LL-37 can damage host cells — a fundamental challenge for therapeutic development
• Mast cell activation: Can trigger mast cell degranulation, potentially causing allergic-type reactions
• Inflammatory potential: In certain contexts (e.g., rosacea), LL-37 drives pathological inflammation
• Clinical safety data is limited to early-phase studies

Legal Status

• United States: Not FDA-approved. Available from peptide suppliers as a research chemical.
• Internationally: Not approved for clinical use in any country.

Cost

• Research-grade: $50–$150 per vial from peptide suppliers (relatively expensive due to synthesis complexity of a 37-amino acid peptide)
• Peptide clinics: $100–$300 per treatment when offered through clinics

Humanin

What It Is

Humanin is a 24-amino acid peptide encoded by the 16S ribosomal RNA gene of the mitochondrial genome. It was discovered in 2001 by Nishimoto and colleagues from the surviving neurons of patients with Alzheimer's disease, suggesting a potential neuroprotective role. It belongs to a class of signaling molecules called mitochondrial-derived peptides (MDPs) — peptides encoded in the mitochondrial genome that function as endocrine and paracrine signals (Hazafa et al., 2021).

Mechanism of Action

• Anti-apoptotic: Binds to and inhibits BAX (a pro-apoptotic protein), preventing mitochondrial membrane permeabilization and downstream cell death cascades
• IGFBP-3 interaction: Binds to insulin-like growth factor binding protein-3 (IGFBP-3), blocking its pro-apoptotic effects
• STAT3 signaling: Activates the STAT3 pathway through the CNTFR/WSX-1/gp130 receptor complex
• Insulin sensitization: Enhances insulin sensitivity through AMPK activation and improved mitochondrial function
• Neuroprotection: Protects neurons against amyloid-beta toxicity, oxidative stress, and excitotoxicity

Source: Hazafa et al., 2021; Gong et al., 2018.

Clinical Evidence

• Alzheimer's disease: Humanin protects neurons against amyloid-beta-induced toxicity in cell culture and animal models. Circulating humanin levels are lower in Alzheimer's patients. No human interventional trials completed (Hazafa et al., 2021)
• Cardiovascular disease: Animal studies show cardioprotective effects in ischemia-reperfusion models and atherosclerosis. Higher circulating humanin levels are associated with better cardiovascular outcomes in observational studies (Cai et al., 2020)
• Type 2 diabetes: Animal studies demonstrate improved insulin sensitivity and beta-cell survival with humanin analogs
• Aging: Circulating humanin levels decline with age across species. Centenarians and their offspring have higher humanin levels than age-matched controls

Limitations: All evidence is preclinical or observational. No human interventional clinical trials have been completed. The peptide's short half-life in vivo requires analog development (e.g., [Gly14]-humanin, or HNG) for potential therapeutic use (Gong et al., 2018).

Dosing Context

Humanin is not approved for clinical use. It has been administered in animal studies via subcutaneous and intraperitoneal injection. Dosing for any potential clinical application should be determined by a qualified healthcare provider in a research or supervised medical setting.

Side Effects

• No significant adverse effects reported in published animal studies
• Human safety data does not exist from interventional studies
• Theoretical concern: Anti-apoptotic properties could theoretically protect cancer cells from programmed death, though some studies suggest humanin has anti-tumor effects in certain cancer types

Legal Status

• United States: Not FDA-approved. Not a controlled substance. Available from specialized peptide suppliers as a research chemical.
• Internationally: Not approved for clinical use in any country.

Cost

• Research-grade: $50–$120 per vial from specialized peptide suppliers
• Humanin analogs (e.g., HNG): May be available at similar pricing from research peptide vendors

MOTS-c

What It Is

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by the mitochondrial genome within the 12S rRNA gene. It was discovered in 2015 by the Cohen laboratory at the University of Southern California. MOTS-c is the first mitochondrial-derived peptide shown to translocate to the cell nucleus and directly regulate nuclear gene expression in response to metabolic stress (Kumagai et al., 2022).

Mechanism of Action

• AMPK activation: Activates AMP-activated protein kinase, a master regulator of cellular energy metabolism — the same pathway activated by exercise and metformin
• Nuclear translocation: Under metabolic stress, MOTS-c moves from the cytoplasm to the nucleus where it regulates gene expression related to antioxidant defense and metabolic adaptation
• Folate-methionine cycle: Inhibits the folate cycle, leading to AICAR accumulation and subsequent AMPK activation
• Insulin sensitization: Improves insulin sensitivity and glucose uptake in skeletal muscle
• Exercise mimetic: Reproduces some metabolic adaptations of exercise in animal models, including improved endurance and metabolic flexibility

Source: Kumagai et al., 2022; Yong et al., 2023.

Clinical Evidence

• Obesity and metabolism: In mouse models, MOTS-c administration prevents diet-induced obesity and improves glucose tolerance. Circulating MOTS-c levels are lower in obese individuals (Yong et al., 2023)
• Exercise response: Human observational studies show circulating MOTS-c levels increase in response to exercise. A study in obese men found that exercise intervention altered MOTS-c levels in reproductive cells (2022)
• Aging: MOTS-c levels decline with age. In mouse models, MOTS-c administration to aged mice improves physical performance and metabolic parameters (Kumagai et al., 2022)
• Type 2 diabetes: Preclinical data shows improved insulin sensitivity. Circulating MOTS-c is lower in type 2 diabetes patients
• Osteoporosis: Animal data suggests MOTS-c may promote osteoblast differentiation and bone formation

Limitations: Nearly all interventional evidence is from animal studies. Human data is primarily observational (measuring circulating levels). No Phase I or Phase II clinical trials have been completed as of this writing (Yong et al., 2023).

Dosing Context

MOTS-c is not approved for clinical use. It has been administered in animal studies via intraperitoneal injection. Dosing for any potential clinical application should be determined by a qualified healthcare provider in a research setting.

Side Effects

• No significant adverse effects reported in published animal studies
• Human safety data from interventional studies does not exist
• Theoretical safety profile is considered favorable given it is an endogenous peptide, but this has not been validated clinically

Legal Status

• United States: Not FDA-approved. Not a controlled substance. Available from specialized peptide suppliers as a research chemical.
• Internationally: Not approved for clinical use in any country.

Cost

• Research-grade: $60–$150 per vial from peptide suppliers
• Peptide clinics: $150–$400 per month when offered through anti-aging or metabolic optimization clinics

Sources & Further Reading

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.